111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
对于存在微血管侵犯的肝细胞癌患者，经导管动脉化疗栓塞术可作为术后辅助治疗的选择性适应证。
Authors Zeng J , Huang H, Tang M, Tao Z, Mo K, Chen W, Su Y, Su J, Liang R , Lin Y, Li L , Wu G , Luo X, Ye J, Mai R
Received 14 August 2025
Accepted for publication 3 December 2025
Published 18 December 2025 Volume 2025:12 Pages 2825—2838
DOI https://doi.org/10.2147/JHC.S560567
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Mohamed Shaker
Jie Zeng,1,2,* Hongyang Huang,1,* Minchao Tang,1,* Zheng Tao,1 Kaixiang Mo,1 Weijie Chen,1 Yuejiao Su,3 Jinting Su,3 Rong Liang,3,4 Yan Lin,3,4 Lequn Li,1 Guobin Wu,1 Xiaoling Luo,4,5 Jiazhou Ye,1,4 Rongyun Mai1,4,5
1Department of Hepatobiliary & Pancreatic Surgery, Guangxi Medical University Cancer Hospital, Guangxi Medical University, Nanning, 530021, People’s Republic of China; 2Department of Physiology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 3Department of Digestive Oncology, Guangxi Medical University Cancer Hospital, Guangxi Medical University, Nanning, 530021, People’s Republic of China; 4Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, 530021, People’s Republic of China; 5Department of Experimental Research, Guangxi Medical University Cancer Hospital, Guangxi Medical University, Nanning, 530021, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiazhou Ye, Email yejiazhou2019@163.com Rongyun Mai, Email mairongyun@sr.gxmu.edu.cn
Background: Microvascular invasion (MVI) serves as a well-established prognostic factor for tumor recurrence and reduced survival following curative hepatectomy in hepatocellular carcinoma (HCC). This investigation aims to assess the therapeutic value of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in HCC patients with MVI and delineate the optimal patient subpopulations for this intervention.
Methods: This retrospective cohort study analyzed patients with MVI in HCC patients who received curative resection from September 2013 to June 2019. After balancing baseline differences between the PA-TACE group and the non-TACE control group using propensity score matching (PSM), the differences in recurrence-free survival (RFS) and overall survival (OS) between the two groups were compared. A multivariate Cox proportional hazards regression model was used to identify independent prognostic factors.
Results: Among 440 evaluable patients, PA-TACE demonstrated statistically significant improvements in both RFS and OS compared to non-TACE management, with consistent results observed in both the entire and propensity score-matched cohorts. Multivariate analysis established PA-TACE as an independent protective predictor for both RFS and OS. Subgroup analyses revealed pronounced clinical benefits in patients exceeding Milan criteria and those presenting with high-risk features including serum AFP ≥ 400 ng/mL, tumor size ≥ 5 cm, Edmondson-Steiner grade III/IV differentiation, M2-type MVI, or major hepatectomy. Notably, no survival advantage was observed in patients within Milan criteria or BCLC-A/B stages.
Conclusion: PA-TACE provides substantial survival enhancement in HCC patients with MVI exceeding Milan criteria or with high-risk features, but offers limited benefit for Milan-eligible cases. Patient selection based on tumor biology is critical for optimizing adjuvant therapy.
Keywords: hepatocellular carcinoma, microvascular invasion, postoperative adjuvant transcatheter arterial chemoembolization, recurrence-free survival, overall survival
1Department of Hepatobiliary & Pancreatic Surgery, Guangxi Medical University Cancer Hospital, Guangxi Medical University, Nanning, 530021, People’s Republic of China; 2Department of Physiology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 3Department of Digestive Oncology, Guangxi Medical University Cancer Hospital, Guangxi Medical University, Nanning, 530021, People’s Republic of China; 4Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, 530021, People’s Republic of China; 5Department of Experimental Research, Guangxi Medical University Cancer Hospital, Guangxi Medical University, Nanning, 530021, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiazhou Ye, Email yejiazhou2019@163.com Rongyun Mai, Email mairongyun@sr.gxmu.edu.cn
Background: Microvascular invasion (MVI) serves as a well-established prognostic factor for tumor recurrence and reduced survival following curative hepatectomy in hepatocellular carcinoma (HCC). This investigation aims to assess the therapeutic value of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in HCC patients with MVI and delineate the optimal patient subpopulations for this intervention.
Methods: This retrospective cohort study analyzed patients with MVI in HCC patients who received curative resection from September 2013 to June 2019. After balancing baseline differences between the PA-TACE group and the non-TACE control group using propensity score matching (PSM), the differences in recurrence-free survival (RFS) and overall survival (OS) between the two groups were compared. A multivariate Cox proportional hazards regression model was used to identify independent prognostic factors.
Results: Among 440 evaluable patients, PA-TACE demonstrated statistically significant improvements in both RFS and OS compared to non-TACE management, with consistent results observed in both the entire and propensity score-matched cohorts. Multivariate analysis established PA-TACE as an independent protective predictor for both RFS and OS. Subgroup analyses revealed pronounced clinical benefits in patients exceeding Milan criteria and those presenting with high-risk features including serum AFP ≥ 400 ng/mL, tumor size ≥ 5 cm, Edmondson-Steiner grade III/IV differentiation, M2-type MVI, or major hepatectomy. Notably, no survival advantage was observed in patients within Milan criteria or BCLC-A/B stages.
Conclusion: PA-TACE provides substantial survival enhancement in HCC patients with MVI exceeding Milan criteria or with high-risk features, but offers limited benefit for Milan-eligible cases. Patient selection based on tumor biology is critical for optimizing adjuvant therapy.
Keywords: hepatocellular carcinoma, microvascular invasion, postoperative adjuvant transcatheter arterial chemoembolization, recurrence-free survival, overall survival